



Fibrosis • Activity • Steatosis



An innovative diagnostic and screening tool for a **COMPLETE LIVER EVALUATION**



LIVERFASt[™] Provides a Full Liver Evaluation for Multiple Etiologies



S-A-F Score Staging⁶

Fibrosis			Activity			Steatosis			
SCORE	STAGE	INTERPRETATION	SCORE	GRADE	INTERPRETATION	SCORE	STAGE	INTERPRETATION	
0.00 - 0.27	FO	No fibrosis	0.00 - 0.29	AO	No activity	0.00 - 0.37	S0	No steatosis (<5%)	
0.28 - 0.48	F1	Mild fibrosis	0.30 - 0.52	A1	Mild activity	0.38 - 0.56	51	Mild steatosis (5-33%)	
0.49 - 0.58	F2	Advanced fibrosis	0.53 - 0.622	A2	Moderate activity	0.50 - 0.50	1		
0.59 - 0.74	F3	Significant fibrosis	0.63 - 0.72	A3	Marked activity	0.57 - 0.68	52	Moderate steatosis (34-66%)	
0.75 - 1.00	F4	Severe fibrosis (cirrhosis)	0.73 - 1.00	A4	Severe activity	0.69 - 1.00	53	Marked steatosis (>67%)	

Distinctive Staging of Three Lesions

LIVERFASt[™] provides a complete liver evaluation with the staging of fibrosis, activity, and steatosis.

	LIVERFASt™	APRI	FIB-4	ELF	NIS4	ProC3	Fibrosure	Fibroscan
Specific for Fibrosis (F)	~	•	•	•	(MIX F.A.S)	(MIX F.S)	<	(BMI-impacted cutoffs)
Specific for Activity (A)	×	×	×	×	×	×	(MIX A.S)	×
Specific for Steatosis (S)	×	×	×	×	×	×	×	×
NASH Staging	•	×	×	×	Only severe NASH	Only NASH Cirrhosis	×	Only severe NASH
No. of Biomarkers	10	2	3	3	4	1	10	US
Assessment Unbiased towards fibrosis	<	(AST)	(AST/ALT)	(non-fasting, circadian rythm)	(A,S)	* (5)	× .	(A,S)

(TE = Transient Elastography, MRI = Magnetic Resonance Imaging, APRI = AST-to-Platelet Ratio Index, ELF = Enhanced Liver Fibrosis, FIB-4 = Fibrosis-4 index)

Simple and Convenient with Immediate Results



Physician prescribes LIVERFASt™ for the patient



Lab analyses 10 biomarkers from **1 blood sample**




Biomarker results and patient specific characteristics input into Fibronostics' proprietary Artificial Intelligence (AI) platform



LIVERFASt[™] results are available immediately

LIVERFASt[™] in non-alcoholic fatty liver (NAFLD) patients^{6,8-9,14}

LIVERFASt[™] Fibrosis score accurately detects cirrhosis, AUROC (95%), in NAFLD patients, with or without type 2 diabetes mellitus (T2DM) and provides results similar to transient elastography (TE), P=NS.⁹ LIVERFASt[™] Steatosis score outperforms ultrasound in the detection of moderate steatosis (Grades S2S3, >33% of hepatocytes) in obese patients and CAP for obese patients with BMI>35Kg/m2 and T2Diabetes.⁹



LIVERFASt[™] identifies NASH even in subjects with normal liver enzymes.

LIVERFASt[™] improves the identification of NASH and demonstrates superior performance to FIB-4.

 AUROC (95% CI) for all stages of NASH

 LIVERFASt
 0.88 (0.75 - 0.94)


 FIB-4
 0.68 (0.54 - 0.77), p<0.0019</td>


Look for NAFLD in patients with Type 2 Diabetes Mellitus, irrespective of liver enzyme levels, due to high risk of disease progression.¹⁴

EASL, 2016

Patients with type 2 diabetes or prediabetes and elevated liver enzymes (ALT) or fatty liver on ultrasound should be evaluated for presence of nonalcoholic steatohepatitis and liver fibrosis. [...] Noninvasive tests, such as fibrosis biomarkers, may be used to assess risk of fibrosis » ¹⁵

American Diabetes Association, 2021





AGE: 60 years old	GENDER:	Male	BODY	MASS INDEX:	38.9*		
Sample Date: March 12,2021							
	Result	Unit		Result	Unit		
alpha-2-Macroglobulin	391	mg/dL	ALT	30	IU/L		
Haptoglobin	57	mg/dL	AST	29	mg/dL		
Apolipoprotein A1	112	mg/dL	Fasting Glucose	99	mg/dL		
Total Bilirubin	0.7	mg/dL	Total Cholesterol	214	mg/dL		
GGT	147	IU/L	Triglycerides	204	mg/dL		

*Warning: This value is out of the 98% range. Check this value.

CLIA# 10D2190357 This report is computer generated. No signature required. AMA CE

United States

3452 Lake Lynda Drive, Bldg 100, Suite 151, Orlando, Florida, 32817

Singapore

79 Science Park Drive #06-01/08 Cintech IV, Singapore 118264

Contact Us

service@fibronostics.com P: 1-888-552-1603 **F**: 1-321-256-6061



Fibronostics specializes in algorithm-based non-invasive diagnostic solutions.

> For more information, please visit www.fibronostics.com

- eferences: "Hepatitis B."World Health Organization, https://www.who.int/news-room/fact-sheets/detail/hepatitis-b "Hepatitis C." World Health Organization, https://www.who.int/news-room/fact-sheets/detail/hepatitis-c "Hepatitis C." World Health Organization, https://www.who.int/news-room/fact-sheets/detail/hepatitis-c Nounossi, Z. M. et al. "Global epidemiology of nonalcoholic fatty liver Glosease meta-analytic assessment of prevalence, incidence, and outcomes." Hepatology. 2016; 64: 73–84 Liangpunsakul, S. et al. "Alcoholic Liver Disease in Asia, Europe, and North America" Gastroenterology. 2016; 150: 1766-1797 Bedossa, P. et al. L. Histologic and noninvasive estimates of liver fibrosis. Clinical Liver Disease, 6: 5-8. Bedossa, P. et al. L. Histologic and noninvasive estimates of liver fibrosis. Clinical Liver Disease, 6: 5-8. Bedossa, P. et al. Histopathological algorithm and scoring system for evaluation of Liver lesions tim morbidly obese patients. Hepatology. 2012;56(5):1751-1759. Jung, E.S., et al. (2016), Interobserver Agreement on Pathologic Features of Liver Biopsy Tissue in Patients with Nonalcoholic Fatty Liver Diseases in NAFLD from a cohort with liver biopsy. Submitted to Hepatology 2020 Jaragvoraphonchai K., et al. Comparative performances of LiverFast, Inflammation Activity and Steatosis (LIVERFASTM) JILSA 2020, 12, 31-49. J. deledinghen V. et al. Comparative performances of LiverFast, VCTE(Fibroscan), and others erum non-invasive tests (NTS) for the diagnosis of advanced chronic Liver diseases in NAFLD from a cohort with liver biopsy. Submitted to Hepatology 2020 Orangvoraphonchai K., et al. Comparative assessment liverfast, with Nonaixer stiverfast, FIB4, APRI and liver stiffness measurement (LSM, Fibroscan) in chronic hepatitis C (CHC) patients with liver biopsy. Journal of the Medical ussociation of Thaliand in press.
- Association of Thailand in press.
 1. Lim S.G., et al. Predictive value of non-invasive methods liverfast, acoustic radiation force impulse (ARFI), FIB-4 and APRI to identify the natural phases of chronic hepatitis B (CHB) infection from the National University Hospital (NUH) CHB study cohort of ingapore. Submitted to AASLD Liver Meeting 2020
 2.1. "Liver Issues That Should Not Be Ignored" Star2.com, https://www.star2.com/health/2018/08/19/liver-issues-not-ignored/
 3. Sarah, D. "Disease progression: Divergent paths" Nature. 2017 November; 551: 592-593
 4. European Association for the Study of the Liver (EASL). "EASL CASD EASD Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease." Journal of Hepatology. 2016 June; 64(6):1388-402
 5. American Diabetes Association. Comprehensive Medical Evaluation and Assessment of Comorbidities: Standards of Medical Care in Diabetes—2021. Diabetes Care 2021 Jan; 44(Supplement 1): \$40-55